What Spruce Biosciences does

Spruce Biosciences is a late-stage biopharmaceutical company developing therapies for rare diseases affecting the endocrine and central nervous systems. The company's core asset is tralesinidase alfa enzyme replacement therapy (TA-ERT), an enzyme replacement therapy acquired from BioMarin Pharmaceutical in April 2025 that targets Sanfilippo Syndrome Type B (MPS IIIB), a fatal ultra-rare pediatric neurodegenerative lysosomal storage disorder affecting fewer than one in 200,000 people in the United States with no currently approved disease-modifying therapies. TA-ERT has demonstrated rapid and durable normalization of cerebrospinal fluid heparan sulfate levels and stabilization of cognitive function, communication skills, motor function, and cortical gray matter volume across 22 patients treated for six years with approximately 6,000 doses, and has received FDA Breakthrough Therapy, Rare Pediatric Disease, Fast Track, and Orphan Drug designations with FDA-confirmed potential for accelerated approval via the CSF HS-NRE surrogate endpoint.

The company's secondary pipeline includes tildacerfont (a CRF1 receptor antagonist for congenital adrenal hyperplasia, with its Japan partnership with Kaken Pharmaceutical terminated March 31, 2026) and SPR202 (an anti-CRH monoclonal antibody in collaboration with Harbour BioMed). Spruce Biosciences is publicly traded on NASDAQ under ticker SPRB and operates as a pre-revenue clinical-stage company preparing for BLA submission in Q4 2026 and potential U.S. commercial launch in late 2026 to mid-2027. The company is building a specialty pharmaceutical commercial organization targeting academic medical centers, specialty pharmacies, and rare disease treatment centers, with H.C. Wainwright projecting potential annual pricing of approximately $800,000 per patient and peak U.S. sales exceeding $150 million.

Spruce Biosciences is funded through a combination of private placements ($53.6M in 2023, $50M in 2025), a $50M venture debt facility with Avenue Capital (January 2026, $15M initially drawn), and a $60M underwritten public offering in April 2026, with cash runway projected into 2H 2027. The company reported a $39M net loss for FY2025 and $12.3M net loss for Q1 2026. As of the April 2026 offering, market capitalization was approximately $96.67M with 91.71% institutional ownership including Carlyle Group, Ikarian Capital, and Wellington Management Group.

Name

Spruce Biosciences

Legal name

Spruce Biosciences, Inc.

Website

https://sprucebiosciences.com

Company type

Public

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

Spruce Biosciences is a late-stage biopharmaceutical company developing tralesinidase alfa enzyme replacement therapy for Sanfilippo Syndrome Type B, an ultra-rare pediatric neurodegenerative disorder with no approved disease-modifying treatments. The company is preparing for a Q4 2026 BLA submission targeting mid-2027 accelerated FDA approval.

Ownership category

akta.pro rank

Product category

Rare Disease Biopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Therapeutic Enzymes & Enzyme Replacement Therapies (ERT) (HLAAAAAK)

akta.pro secondary industries

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy) (HLAAAIAK)

Keywords

• Rare disease therapeutics
• Enzyme replacement therapy
• Biopharmaceutical development
• Lysosomal storage disorders
• Endocrine disorder treatments

Headquarters

HQ city

South San Francisco

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Spruce Biosciences expects to generate revenue through the sale of its approved therapies, primarily tralesinidase alfa (TA-ERT) for Sanfilippo Syndrome Type B, with anticipated potential annual pricing of approximately $800,000 per patient and projected peak U.S. sales exceeding $150 million. The company is preparing for a potential US commercial launch in late 2026 following BLA approval.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Spruce Biosciences is a late-stage biopharmaceutical company developing novel therapies for rare diseases targeting the endocrine and neurological systems. Its lead candidate, tralesinidase alfa enzyme replacement therapy (TA-ERT), is being developed for Sanfilippo Syndrome Type B (MPS IIIB), an ultra-rare fatal pediatric neurodegenerative disorder, with a BLA submission planned for Q4 2026. Additional pipeline assets include tildacerfont for congenital adrenal hyperplasia (CAH) and SPR202, an anti-CRH monoclonal antibody developed in collaboration with Harbour BioMed.

Product overview

Spruce Biosciences is a late-stage biopharmaceutical company developing novel therapies for rare diseases, primarily focusing on neurological and endocrine disorders with significant unmet medical need. The company's core product portfolio consists of three therapeutic candidates: TA-ERT (tralesinidase alfa enzyme replacement therapy), an enzyme replacement therapy for Sanfilippo Syndrome Type B (MPS IIIB); Tildacerfont, a CRF1 receptor antagonist for rare endocrine disorders including congenital adrenal hyperplasia; and SPR202, an anti-CRH monoclonal antibody. The company is preparing for a potential Biologics License Application submission for TA-ERT in Q4 2026 with anticipated FDA accelerated approval in mid-2027.

Differentiator

Problem solved

Functional benefit

Products and services

• TA-ERT (Tralesinidase Alfa Enzyme Replacement Therapy) Enzyme replacement therapy for Sanfilippo Syndrome Type B (MPS IIIB), an ultra-rare fatal pediatric neurodegenerative lysosomal storage disorder. The therapy normalizes cerebrospinal fluid heparan sulfate levels and has demonstrated rapid and durable biomarker normalization and stabilization of cognitive function, communication skills, motor function, and cortical gray matter volume over six years of treatment across 22 patients and approximately 6,000 doses. TA-ERT has received FDA Breakthrough Therapy Designation, Rare Pediatric Disease Designation, Fast Track Designation, and Orphan Drug Designation.
• Tildacerfont CRF1 receptor antagonist product candidate for the treatment of congenital adrenal hyperplasia (CAH) and other rare endocrine disorders. Originally the company's lead asset and funded by a $53.6M private placement in February 2023 with clinical trial results expected in late 2023, 2024, and 2025.
• SPR202

Quantifiable outcome

• Rapid and durable normalization of cerebral spinal fluid heparan sulfate levels over 6 years of treatment with approximately 6,000 doses
• +4 more outcomes

Segments2 records

Ideal customer profiles2 records

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered minor and core.

• Kaken PharmaceuticalminorStrategic or Co-development Partner · 31 March 2026Spruce Biosciences and Kaken Pharmaceutical had a collaboration and license agreement for the development, manufacture, and commercialization of tildacerfont for congenital adrenal hyperplasia (CAH) in Japan. The agreement, including initial payments and milestone targets, was mutually terminated effective March 31, 2026 following a comprehensive review. All licenses and rights granted to Kaken ceased, with no future milestone payments or royalties to Spruce.
• Harbour BioMed (HBM Holdings)coreStrategic or Co-development PartnerHarbour BioMed exercised a warrant to acquire common stock in Spruce Biosciences, resulting in approximately 3.8% ownership of total outstanding shares and 3.1% of fully diluted shares. The warrant originated from a license and collaboration agreement between HBM Alpha Therapeutics (incubated by Harbour BioMed) and Spruce, aimed at advancing SPR202, an anti-corticotropin-releasing hormone monoclonal antibody for disorders including congenital adrenal hyperplasia. This transaction transformed the relationship from a traditional licensor-licensee arrangement into a more aligned strategic partnership.

Scale indicators14 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• BioMarin Pharmaceutical: BioMarin originally developed tralesinidase alfa and sold it to Spruce in April 2025. BioMarin remains the most directly comparable rare-disease ERT company (Naglazyme, Vimizim, Aldurazyme co-developer), sharing the same MPS patient advocacy and specialist channel.
• Ultragenyx Pharmaceutical: Ultragenyx markets multiple enzyme and biologic replacement therapies for ultra-rare diseases (Crysvita, Mepsevii, Dojolvi). Comparable business model focused on small patient populations, premium pricing, and rare-disease commercial infrastructure.

Broad incumbents

• Sanofi (Genzyme): Genzyme pioneered lysosomal storage disorder ERTs (Cerezyme, Fabrazyme, Aldurazyme). Sanofi's rare-disease franchise provides an established benchmark for TA-ERT's commercial trajectory and pricing benchmarks in MPS/lysosomal disorders.
• Takeda Pharmaceutical: Through the Shire acquisition, Takeda markets Replagal, Elaprase, and VPRIV (ERTs for Fabry, Hunter, and Gaucher diseases). Directly comparable commercial infrastructure in lysosomal storage disorder specialty channels.
• Alexion Pharmaceuticals (AstraZeneca Rare Disease): Alexion is the archetype ultra-rare disease commercial organization; several of Spruce's newly hired commercial leaders (Brian Walls, Darren Johnson) previously launched products at Alexion. Comparable patient identification and specialty distribution expertise.

Emerging players

• Denali Therapeutics: Denali is developing enzyme replacement therapies and small molecules for lysosomal storage diseases and neurodegeneration, including MPS programs. Overlapping therapeutic targets and biomarker-driven development approach.
• REGENXBIO: REGENXBIO is advancing AAV-based gene therapies for MPS I (Hurler syndrome) and MPS II, representing the principal long-term competitive threat to chronic ERT administration in the MPS space.
• BridgeBio Pharma: BridgeBio develops therapies for genetic diseases with high unmet need, including rare endocrine and CNS disorders. Comparable small-cap, multi-asset rare-disease biotech profile and similar reliance on accelerated approval pathways.
• Orchard Therapeutics: Orchard focuses on gene therapies for rare pediatric metabolic and neurodegenerative diseases, including MPS disorders. Represents an emerging modality that could compete with chronic ERTs like TA-ERT.

Others

• Moderna: Moderna's mRNA platform is being explored for in vivo enzyme expression in rare metabolic disorders, representing an adjacent modality that could eventually substitute for ERTs in diseases like MPS IIIB.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/spruce-biosciences

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Funding overview

Funding rounds8 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Spruce Biosciences